Can RAS inhibitors affect the course of hypertrophic cardiomyopathy?

Lancet Diabetes Endocrinol. 2015 Feb;3(2):95-6. doi: 10.1016/S2213-8587(14)70253-0. Epub 2014 Dec 19.

Authors

Robert M Cooper¹, Rodney H Stables²

Affiliations

¹ Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK. Electronic address: [email protected].
² Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK.

PMID: 25533773
DOI: 10.1016/S2213-8587(14)70253-0

No abstract available

Publication types

Comment

MeSH terms

Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Cardiomyopathy, Hypertrophic / drug therapy*
Female
Humans
Hypertrophy, Left Ventricular / drug therapy*
Losartan / therapeutic use*
Male

Substances

Angiotensin II Type 1 Receptor Blockers
Losartan